ID   CH56
AC   CVCL_V563
SY   BCSCH56
DR   cancercelllines; CVCL_V563
DR   Cosmic; 2076361
DR   Wikidata; Q54811639
RX   PubMed=23958880;
CC   Sequence variation: Mutation; HGNC; HGNC:5383; IDH2; Simple; p.Arg172Ser (c.516G>C); ClinVar=VCV000375985; Zygosity=Unspecified (PubMed=23958880).
CC   Derived from site: In situ; Bone, humerus; UBERON=UBERON_0000976.
ST   Source(s): PubMed=23958880
ST   Amelogenin: X
ST   D16S539: 12
ST   D18S51: 15,26
ST   D19S433: 12,13
ST   D21S11: 29,30
ST   D2S1338: 20,23
ST   D3S1358: 16
ST   D8S1179: 11,14
ST   FGA: 24
ST   TH01: 6,9
ST   vWA: 14,18
DI   NCIt; C7155; Primary central chondrosarcoma
DI   ORDO; Orphanet_55880; Chondrosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   64Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 19-12-24; Version: 16
//
RX   PubMed=23958880; DOI=10.1038/labinvest.2013.101;
RA   Monderer D., Luseau A., Bellec A., David E., Ponsolle S., Saiagh S.,
RA   Bercegeay S., Piloquet P., Denis M.G., Lode L., Redini F., Biger M.,
RA   Heymann D., Heymann M.-F., Le Bot R., Gouin F., Blanchard F.;
RT   "New chondrosarcoma cell lines and mouse models to study the link
RT   between chondrogenesis and chemoresistance.";
RL   Lab. Invest. 93:1100-1114(2013).
//